Effect of JumpstartMD, a Commercial Low-Calorie Low-Carbohydrate Physician-Supervised Weight Loss Program, on 22,407 Adults.

IF 3.8 Q2 ENDOCRINOLOGY & METABOLISM Journal of Obesity Pub Date : 2020-01-21 eCollection Date: 2020-01-01 DOI:10.1155/2020/8026016
Sean Bourke, John Magaña Morton, Paul Williams
{"title":"Effect of JumpstartMD, a Commercial Low-Calorie Low-Carbohydrate Physician-Supervised Weight Loss Program, on 22,407 Adults.","authors":"Sean Bourke,&nbsp;John Magaña Morton,&nbsp;Paul Williams","doi":"10.1155/2020/8026016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Commercial weight loss programs provide valuable consumer options for those desiring support. Several commercial programs are reported to produce ≥3-fold greater weight loss than self-directed dieting. The effectiveness of JumpstartMD, a commercial pay-as-you-go program that emphasizes a low-to-very-low-carbohydrate real-food diet and optional pharmacologic treatment without prepackaged meals or meal replacement, has not previously been described.</p><p><strong>Methods: </strong>Completer and last observation carried forward (LOCF) of clinic-measured weight loss (kg) in 18,769 female and 3638 male JumpstartMD participants.</p><p><strong>Results: </strong>Completers lost (mean ± SE) 8.7 ± 0.04 kg, 9.5 ± 0.04% with 44.5 ± 0.5% achieving ≥10% weight loss at 3 months (mo, <i>N</i> = 14,999 completers); 11.8 ± 0.1 kg, 12.6 ± 0.1% with 66.4 ± 0.6% achieving ≥10% weight loss at 6 mo (<i>N</i> = 11,805); and 11.5 ± 0.2 kg, 12.0 ± 0.2% with 57.6 ± 0.9% achieving ≥10% weight loss at 12 mo (<i>N</i> = 8514). LOCF estimates were -6.5 ± 0.03 kg, -7.2 ± 0.03% with 27.1 ± 0.3% achieving ≥10% weight loss at 3 mo; -7.7 ± 0.04 kg, -8.5 ± 0.04% with 36.3 ± 0.3% achieving ≥10% weight loss at 6 mo; and -7.7 ± 0.1 kg, -8.4 ± 0.1% with 34.6 ± 0.3% achieving ≥10% weight loss after 12 mo. Frequent health coach meetings was a major determinant of weight loss, with women and men attending ≥75% of their weekly appointments losing 8.8 ± 0.04 and 11.9 ± 0.1 kg, respectively, after 3 mo, 13.1 ± 0.1 and 16.5 ± 0.3 kg after 6 mo, and 16.5 ± 0.3 and 19.4 ± 0.8 kg after 12 mo. Phentermine and phendimetrazine had a minor effect in women only at 1 (6.1% greater weight loss than untreated), 2 (4.1%), and 3 mo (1.2%), but treated patients showed longer enrollment than nontreated during the first 3 (females: +0.4 ± 0.01; males: +0.3 ± 0.04 mo), 6 (females: +1.1 ± 0.04; males: +1.0 ± 0.1 mo), and 12 mo (females: +2.7 ± 0.1; males: +2.4 ± 0.2 mo). JumpstartMD produced generally greater weight loss than published reports for other real-food and prepackaged-meal commercial programs and somewhat greater or comparable losses to meal replacement diets.</p><p><strong>Conclusion: </strong>A one-on-one medically supervised program that emphasized real low-carbohydrate foods produced effective weight loss, particularly in those attending ≥75% of their weekly appointments.</p>","PeriodicalId":16628,"journal":{"name":"Journal of Obesity","volume":"2020 ","pages":"8026016"},"PeriodicalIF":3.8000,"publicationDate":"2020-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/8026016","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obesity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/8026016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Commercial weight loss programs provide valuable consumer options for those desiring support. Several commercial programs are reported to produce ≥3-fold greater weight loss than self-directed dieting. The effectiveness of JumpstartMD, a commercial pay-as-you-go program that emphasizes a low-to-very-low-carbohydrate real-food diet and optional pharmacologic treatment without prepackaged meals or meal replacement, has not previously been described.

Methods: Completer and last observation carried forward (LOCF) of clinic-measured weight loss (kg) in 18,769 female and 3638 male JumpstartMD participants.

Results: Completers lost (mean ± SE) 8.7 ± 0.04 kg, 9.5 ± 0.04% with 44.5 ± 0.5% achieving ≥10% weight loss at 3 months (mo, N = 14,999 completers); 11.8 ± 0.1 kg, 12.6 ± 0.1% with 66.4 ± 0.6% achieving ≥10% weight loss at 6 mo (N = 11,805); and 11.5 ± 0.2 kg, 12.0 ± 0.2% with 57.6 ± 0.9% achieving ≥10% weight loss at 12 mo (N = 8514). LOCF estimates were -6.5 ± 0.03 kg, -7.2 ± 0.03% with 27.1 ± 0.3% achieving ≥10% weight loss at 3 mo; -7.7 ± 0.04 kg, -8.5 ± 0.04% with 36.3 ± 0.3% achieving ≥10% weight loss at 6 mo; and -7.7 ± 0.1 kg, -8.4 ± 0.1% with 34.6 ± 0.3% achieving ≥10% weight loss after 12 mo. Frequent health coach meetings was a major determinant of weight loss, with women and men attending ≥75% of their weekly appointments losing 8.8 ± 0.04 and 11.9 ± 0.1 kg, respectively, after 3 mo, 13.1 ± 0.1 and 16.5 ± 0.3 kg after 6 mo, and 16.5 ± 0.3 and 19.4 ± 0.8 kg after 12 mo. Phentermine and phendimetrazine had a minor effect in women only at 1 (6.1% greater weight loss than untreated), 2 (4.1%), and 3 mo (1.2%), but treated patients showed longer enrollment than nontreated during the first 3 (females: +0.4 ± 0.01; males: +0.3 ± 0.04 mo), 6 (females: +1.1 ± 0.04; males: +1.0 ± 0.1 mo), and 12 mo (females: +2.7 ± 0.1; males: +2.4 ± 0.2 mo). JumpstartMD produced generally greater weight loss than published reports for other real-food and prepackaged-meal commercial programs and somewhat greater or comparable losses to meal replacement diets.

Conclusion: A one-on-one medically supervised program that emphasized real low-carbohydrate foods produced effective weight loss, particularly in those attending ≥75% of their weekly appointments.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
JumpstartMD是一个商业低热量低碳水化合物的医生监督减肥计划,对22,407名成年人的影响。
背景:商业减肥计划为那些渴望支持的人提供了有价值的消费者选择。据报道,一些商业项目的减肥效果比自主节食效果好3倍以上。JumpstartMD是一种商业现收现付计划,强调低碳水化合物至极低碳水化合物的饮食和可选的药物治疗,不需要预先包装的膳食或代餐,其有效性此前没有被描述过。方法:18769名女性和3638名男性JumpstartMD参与者临床测量体重减轻(kg)的完成和最后观察结转(LOCF)。结果:3个月完成者体重减轻(平均±SE) 8.7±0.04 kg,其中9.5±0.04%,44.5±0.5%体重减轻≥10% (mo, N = 14,999);11.8±0.1公斤,12.6±0.1%和66.4±0.6%达到≥10%体重在6 mo (N = 11805);12个月体重减轻11.5±0.2 kg, 12.0±0.2%,57.6±0.9% (N = 8514)。LOCF估计为-6.5±0.03 kg, -7.2±0.03%,其中27.1±0.3%在3个月时体重减轻≥10%;-7.7±0.04公斤,-8.5±0.04%和36.3±0.3%实现减肥6 mo≥10%;12个月后体重减轻-7.7±0.1 kg, -8.4±0.1%,34.6±0.3%达到≥10%。频繁的健康教练会议是减肥的主要决定因素,女性和男性参加≥75%的每周预约,3个月后分别减掉8.8±0.04和11.9±0.1 kg, 6个月后分别减掉13.1±0.1和16.5±0.3 kg, 12个月后分别减掉16.5±0.3和19.4±0.8 kg。芬特明和苯地美嗪仅在1个月(比未治疗的体重减轻6.1%)、2个月(4.1%)和3个月(1.2%)时对女性有轻微影响,但在前3个月,接受治疗的患者比未接受治疗的患者入组时间更长(女性:+0.4±0.01;男性:+0.3±0.04月),6(女性:+1.1±0.04月;男性:+ 1.0±0.1帽),12莫(女性:+ 2.7±0.1;男性:+2.4±0.2个月)。JumpstartMD产生的减肥效果通常比发表的其他真实食品和预包装食品的商业计划更大,比代餐饮食更大或相当。结论:一对一的医学监督项目强调真正的低碳水化合物食物,可以有效地减轻体重,特别是那些每周参加≥75%的预约的人。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Obesity
Journal of Obesity ENDOCRINOLOGY & METABOLISM-
CiteScore
7.50
自引率
3.00%
发文量
19
审稿时长
21 weeks
期刊介绍: Journal of Obesity is a peer-reviewed, Open Access journal that provides a multidisciplinary forum for basic and clinical research as well as applied studies in the areas of adipocyte biology & physiology, lipid metabolism, metabolic syndrome, diabetes, paediatric obesity, genetics, behavioural epidemiology, nutrition & eating disorders, exercise & human physiology, weight control and health risks associated with obesity.
期刊最新文献
Behavioral Determinants of Childhood Obesity in the United States: An Exploratory Study. Association between Socioeconomic Position of the Family and Adolescent Obesity in Germany-Analysis of the Mediating Role of Familial Determinants. Body Mass Index and Prevalence of Obesity in Brazilian Adult Women: Temporal Comparison of Repeated Population-Based Cross-Sectional Surveys. Overweight and Obesity Among In-School Children and Adolescents (5-19 Years) in Ghana: A Scoping Review of Prevalence and Risk Factors. Genetic Variations in AMPK, FOXO3A, and POMC Increase the Risk of Extreme Obesity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1